Evaluation of Periprocedural Safety and Efficacy of Dabigatran, Rivaroxaban, Apixaban and Edoxaban During Catheter Ablation for Atrial Fibrillation

被引：0
|
作者：
Tohoku, Shota
Hiroshima, Kenichi
Nagashima, Michio
Morita, Junji
Iseda, Takahiro
Ando, Kengo
Ando, Kenji
机构：
来源：
CIRCULATION | 2016年 / 134卷
关键词：
Ablation; Anticoagulants; Dabigatran; Rivoraxaban; Apixaban;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
16578
引用
收藏
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [32] Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Giorgi, Mariano A.
    Cohen Arazi, Hernan
    Gonzalez, Claudio D.
    Di Girolamo, Guillermo
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (04) : 567 - 577
  • [33] Meta-Analysis of Efficacy and Safety of Apixaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Lu, Dasheng
    Liu, Qian
    Wang, Kai
    Zhang, Qi
    Shan, Qi-Jun
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2016, 39 (01): : 54 - 59
  • [34] Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri-procedural period of catheter ablation for atrial fibrillation
    Naito, Kazuya
    Nakano, Masataka
    Iwasa, Atsushi
    Maeno, Yoshio
    Shintani, Yoshiaki
    Yamakawa, Takeshi
    Miyashita, Kotaro
    Oyama, Keishiro
    Nakai, Daisuke
    Katagiri, Masaya
    Kido, Hideaki
    Masuda, Shinichiro
    Kohashi, Keiichi
    Kawamata, Tetsuya
    Tanimoto, Shuzou
    Masuda, Naoki
    Ogata, Nobuhiko
    Isshiki, Takaaki
    JOURNAL OF ARRHYTHMIA, 2020, 36 (04) : 634 - 641
  • [35] Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study
    Lau, Wallis C. Y.
    Torre, Carmen Olga
    Man, Kenneth K. C.
    Stewart, Henry Morgan
    Seager, Sarah
    Van Zandt, Mui
    Reich, Christian
    Li, Jing
    Brewster, Jack
    Lip, Gregory Y. H.
    Hingorani, Aroon D.
    Wei, Li
    Wong, Ian C. K.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (11) : 1515 - +
  • [36] Network meta-analysis of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation
    Marx, S.
    Diener, H. -C.
    Harenberg, J.
    Lip, G.
    Marder, V.
    Wehling, M.
    Weiss, C.
    EUROPEAN HEART JOURNAL, 2012, 33 : 815 - 815
  • [37] Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation
    Nagao, Tomoyuki
    Inden, Yasuya
    Shimano, Masayuki
    Fujita, Masaya
    Yanagisawa, Satoshi
    Kato, Hiroyuki
    Ishikawa, Shinji
    Miyoshi, Aya
    Okumura, Satoshi
    Ohguchi, Shiou
    Yamamoto, Toshihiko
    Yoshida, Naoki
    Hirai, Makoto
    Murohara, Toyoaki
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2015, 38 (02): : 155 - 163
  • [38] Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital
    Yamazaki-Nishioka, Miho
    Kogiku, Minoru
    Noda, Masayuki
    Endo, Sumio
    Takekawa, Mitsuru
    Kishi, Hirohisa
    Ota, Miki
    Notsu, Yuki
    Shimizu, Makiko
    Yamazaki, Hiroshi
    XENOBIOTICA, 2019, 49 (09) : 1001 - 1006
  • [39] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [40] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
12345